Leerink Partnrs Analysts Raise Earnings Estimates for IDYA

Key Points

• Investment analysts at Leerink Partnrs raised their Q3 2025 earnings per share estimate for IDEAYA Biosciences from ($0.81) to ($0.80), while also providing forecasts for subsequent quarters through FY2027.
• Shares of IDEAYA Biosciences have seen a range between a fifty-two week low of $13.45 and a high of $40.74, with the stock currently trading around $23.10.
• Multiple analysts have issued ratings on IDEAYA, with an average rating of "Moderate Buy" and a consensus price target of $48.09.

IDEAYA Biosciences, Inc. (NASDAQ:IDYA - Free Report) - Analysts at Leerink Partnrs lifted their Q3 2025 EPS estimates for IDEAYA Biosciences in a note issued to investors on Wednesday, August 6th. Leerink Partnrs analyst A. Berens now anticipates that the company will earn ($0.80) per share for the quarter, up from their prior estimate of ($0.81). The consensus estimate for IDEAYA Biosciences' current full-year earnings is ($3.07) per share. Leerink Partnrs also issued estimates for IDEAYA Biosciences' Q4 2025 earnings at ($1.03) EPS, FY2025 earnings at ($3.53) EPS, FY2026 earnings at ($3.88) EPS and FY2027 earnings at ($3.74) EPS.

Several other research analysts have also commented on the stock. TD Cowen initiated coverage on shares of IDEAYA Biosciences in a research note on Tuesday, July 22nd. They issued a "buy" rating for the company. Wells Fargo & Company initiated coverage on shares of IDEAYA Biosciences in a research note on Thursday, June 26th. They issued an "overweight" rating and a $44.00 price objective for the company. JPMorgan Chase & Co. raised their price objective on shares of IDEAYA Biosciences from $66.00 to $72.00 and gave the company an "overweight" rating in a research note on Monday, July 28th. The Goldman Sachs Group raised shares of IDEAYA Biosciences to a "hold" rating and set a $25.00 price objective for the company in a research note on Thursday, July 10th. Finally, Royal Bank Of Canada raised shares of IDEAYA Biosciences from an "outperform" rating to a "moderate buy" rating and lowered their price objective for the company from $57.00 to $30.00 in a research note on Wednesday, July 9th. Three equities research analysts have rated the stock with a hold rating and ten have assigned a buy rating to the stock. According to data from MarketBeat, IDEAYA Biosciences presently has a consensus rating of "Moderate Buy" and a consensus price target of $48.09.

IDEAYA Biosciences Stock Down 0.4%

IDYA stock traded down $0.09 during mid-day trading on Monday, hitting $24.33. 195,635 shares of the company were exchanged, compared to its average volume of 1,144,914. The business has a fifty day simple moving average of $22.62 and a 200-day simple moving average of $20.39. IDEAYA Biosciences has a 12-month low of $13.45 and a 12-month high of $40.74. The firm has a market capitalization of $2.13 billion, a P/E ratio of -6.41 and a beta of 0.09.

IDEAYA Biosciences (NASDAQ:IDYA - Get Free Report) last announced its earnings results on Tuesday, August 5th. The company reported ($0.88) earnings per share for the quarter, missing the consensus estimate of ($0.85) by ($0.03). The business had revenue of $6.00 million for the quarter, compared to the consensus estimate of $3.48 million. IDEAYA Biosciences's revenue for the quarter was up NaN% compared to the same quarter last year. During the same period in the previous year, the business posted ($0.68) earnings per share.

Institutional Trading of IDEAYA Biosciences

Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Geode Capital Management LLC increased its holdings in shares of IDEAYA Biosciences by 2.2% in the 4th quarter. Geode Capital Management LLC now owns 1,988,681 shares of the company's stock valued at $51,121,000 after acquiring an additional 43,226 shares during the period. Oppenheimer Asset Management Inc. grew its position in IDEAYA Biosciences by 33.2% in the 1st quarter. Oppenheimer Asset Management Inc. now owns 11,560 shares of the company's stock valued at $189,000 after buying an additional 2,884 shares during the last quarter. Rhumbline Advisers grew its position in IDEAYA Biosciences by 9.6% in the 1st quarter. Rhumbline Advisers now owns 124,437 shares of the company's stock valued at $2,038,000 after buying an additional 10,876 shares during the last quarter. Palumbo Wealth Management LLC grew its position in IDEAYA Biosciences by 65.8% in the 1st quarter. Palumbo Wealth Management LLC now owns 22,402 shares of the company's stock valued at $367,000 after buying an additional 8,893 shares during the last quarter. Finally, Deerfield Management Company L.P. Series C grew its position in IDEAYA Biosciences by 5.5% in the 4th quarter. Deerfield Management Company L.P. Series C now owns 2,736,000 shares of the company's stock valued at $70,315,000 after buying an additional 142,000 shares during the last quarter. Institutional investors and hedge funds own 98.29% of the company's stock.

IDEAYA Biosciences Company Profile

IDEAYA Biosciences, Inc, a synthetic lethality-focused precision medicine oncology company, discovers and develops targeted therapeutics for patient populations selected using molecular diagnostics in the United States. The company's products in development include IDE196, a protein kinase C inhibitor that is in Phase 2/3 clinical trials for genetically defined cancers having GNAQ or GNA11 gene mutations; IDE397, a methionine adenosyltransferase 2a inhibitor that is in Phase 1/2 clinical trials for patients with solid tumors having methylthioadenosine phosphorylase gene deletions, such as non-small cell lung, bladder, gastric, and esophageal cancers; IDE161, a poly ADP-ribose glycohydrolase inhibitor that is in Phase 1 clinical trial to treat tumors with homologous recombination deficiency (HRD), and other genetic or molecular signatures; GSK101, a Pol Theta Helicase inhibitor that is in Phase 1 clinical trial for the treatment of tumors with BRCA or other homologous recombination, and HRD mutations; and Werner Helicase inhibitors for tumors with high microsatellite instability.